Clinical trial · Observational
Diagnosis Value of SEMA4C in Breast Cancer
NCT03662633CI-TRIAL-00061576unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm Female | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Benign breast tumor group | Diagnostic Test | — | UNRESOLVED |
| Breast cancer group | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Breast cancer group
- description
- Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
- interventionNames
- Diagnostic Test: Breast cancer group
- label
- Benign breast tumor group
- description
- Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
- interventionNames
- Diagnostic Test: Benign breast tumor group
Primary outcomes (1)
- measure
- Diagnostic potential of SEMA4C as a biomarker for breast cancer
- timeFrame
- At the time of inclusion
- description
- Analyzing the predictive value of SEMA4C in the diagnosis of breast cancer.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Receiving no treatment before diagnosis * Establishing Diagnosis according to biopsy or surgery Exclusion Criteria: * Patients who are not mentally capable of giving written informed consent * Clinical data missing * Serum samples doesn't qualified * Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results
References
Publications (2)
- BACKGROUNDWei JC, Yang J, Liu D, Wu MF, Qiao L, Wang JN, Ma QF, Zeng Z, Ye SM, Guo ES, Jiang XF, You LY, Chen Y, Zhou L, Huang XY, Zhu T, Meng L, Zhou JF, Feng ZH, Ma D, Gao QL. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C. Clin Cancer Res. 2017 Jan 1;23(1):214-224. doi: 10.1158/1078-0432.CCR-16-0741. Epub 2016 Jul 8. PMID 27401250
- BACKGROUNDGurrapu S, Pupo E, Franzolin G, Lanzetti L, Tamagnone L. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018 Jul;25(7):1259-1275. doi: 10.1038/s41418-018-0097-4. Epub 2018 Mar 19. PMID 29555978